News ViroGates A/S

Equities

VIRO

DK0061030574

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:52 2024-04-26 am EDT			5-day change	1st Jan Change
6.5 ^DKK	-11.92%		+8.33%	+7.97%

Apr. 15	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI
Mar. 21	ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Resolutions from the Annual General Meeting of ViroGates A/S	Apr. 25	AQ
ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA	Apr. 15	AQ
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	Apr. 15	CI
ViroGates gives notice to convene the Annual General Meeting on 25 April 2024	Apr. 10	AQ
ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage	Mar. 21	AQ
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S	Dec. 21	AQ
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	Dec. 21	AQ
ViroGates publishes its financial calendar for 2024	Dec. 21	AQ
ViroGates announces financial guidance for 2024	Dec. 21	AQ
ViroGates A/S Provides Earnings Guidance for the Year 2024	Dec. 21	CI
ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered	Dec. 19	AQ
ViroGates announces the outcome of its rights issue	Dec. 15	AQ
ViroGates A/S : Most interesting suPAR studies of 2023	Dec. 08	PU
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	Dec. 07	AQ
ViroGates A/S : Clinical role of suPAR in the prognosis of patients in the emergency setting and its influence on risk stratification	Dec. 06	PU
The subscription period in ViroGates’ rights issue begins today	Nov. 30	AQ
Resolutions from the Extraordinary General Meeting of ViroGates A/S	Nov. 24	AQ
ViroGates A/S : Social isolation in mid-adulthood is associated with elevated suPAR	Nov. 23	PU
ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 2023	Nov. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ViroGates A/S

Equities

VIRO

DK0061030574

Summary

Filters